NCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
Exelixis
Memorial Sloan Kettering Cancer Center
Centre Leon Berard
Indiana University
Dana-Farber Cancer Institute
University of Pittsburgh